AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Methanethiol oxidase

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.

Our library is unique due to several crucial aspects:

  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

Q13228

UPID:

SBP1_HUMAN

Alternative names:

56 kDa selenium-binding protein; Selenium-binding protein 1

Alternative UPACC:

Q13228; A6NML9; A6PVW9; B2RDR3; B4DKP6; B4E1F3; Q49AQ8; Q96GX7

Background:

Methanethiol oxidase, also known as Selenium-binding protein 1, plays a crucial role in the oxidation of methanethiol, a compound produced by gut bacteria. This protein, with alternative names such as 56 kDa selenium-binding protein, is pivotal in the detoxification of sulfur-containing metabolites, thereby preventing their accumulation in the body.

Therapeutic significance:

The deficiency of Methanethiol oxidase leads to extraoral halitosis, a condition marked by a distinct cabbage-like breath odor due to elevated levels of sulfur-containing compounds. Understanding the role of Methanethiol oxidase could open doors to potential therapeutic strategies for treating this malodor condition.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.